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Regulation of dopaminergic function: an [18F]-DOPA PET
apomorphine challenge study in humans.
S Jauhar1, M Veronese2, M Rogdaki3, M Bloomﬁeld3, S Natesan1, F Turkheimer2, S Kapur1 and OD Howes1,3,4
Dopaminergic function has a key role in normal brain function, dopaminergic dysfunction being implicated in numerous
neuropsychiatric disorders. Animal studies show that dopaminergic stimulation regulates dopaminergic function, but it is not
known whether this exists in humans. In the ﬁrst study (study 1), we measured dopamine synthesis capacity (indexed as Ki
cer) to
identify the relationship between baseline and change in Ki
cer under resting conditions for comparison with effects of dopaminergic
stimulation. In the second study (study 2), we used a within-subjects design to test effects of dopaminergic stimulation on
dopamine synthesis capacity. In study 1, eight volunteers received two 18F-DOPA scans on separate days, both at rest. In study 2,
12 healthy male volunteers received two 18F-DOPA positron emission tomographic (PET) scans after treatment with either the
dopamine partial agonist apomorphine (0.03 or 0.005 mg kg− 1) or placebo. In study 1, no signiﬁcant correlation was found between
baseline and change in dopamine synthesis capacity between scans (r=− 0.57, n= 8, P= 0.17, two-tailed). In study 2, a signiﬁcant
negative correlation was found between baseline dopamine synthesis capacity and percentage change in dopamine synthesis
capacity after apomorphine challenge (r=− 0.71, n= 12, P= 0.01, two-tailed). This correlation was signiﬁcantly different (Po0.01)
from the correlation between baseline and change in dopamine synthesis capacity under unstimulated conditions. One-way
repeated-measures analysis of variance showed a signiﬁcant group (study 1/study 2) × time interaction (F(1,18) = 11.5, P= 0.003).
Our ﬁndings suggest that regulation of dopamine synthesis capacity by apomorphine depends on baseline dopamine function,
consistent with dopamine stimulation stabilizing dopaminergic function. Loss of this autoregulation may contribute to
dopaminergic dysfunction in brain disorders such as schizophrenia, substance dependence, and Parkinson's disease.
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INTRODUCTION
Since its discovery in 1957,1 the neuromodulator dopamine has
been shown to have a key role in regulating affect, attention,
motivation,2 reward,3 sleep4 and voluntary movement.5 Variation
in dopamine synthesis capacity (DSC) has been linked to
alterations in a number of these functions,6,7 and may have a
pathoetiological role in a number of neuropsychiatric disorders,
including attention deﬁcit hyperactivity disorder (ADHD),8
Parkinson’s disease,9 schizophrenia10,11 and substance
dependence.12 Speciﬁcally, elevated DSC, as measured by [18F]-
DOPA, is seen in people with schizophrenia13,14 and in the
prodrome to psychosis,15,16 whereas DSC is reduced in ADHD17
and Parkinson’s disease.18 People with substance dependence
also show alterations in DSC in some although not all studies.19–21
Thus, determining the regulation of DSC is likely to be
important for understanding and treating a number of brain
disorders. Preclinical studies have shown that dopamine agonists
at dopamine D1 and dopamine D2 receptors exert regulatory
effects on DSC through three main mechanisms:
1. Terminal negative feedback, through presynaptic autoreceptors
(mainly through D2 receptors), on dopamine nerve terminals in
the striatum.22–24
2. ‘Long loop’ negative feedback, involving a direct striatonigral
pathway, stimulated by postsynaptic receptors and an indirect
striatopallidal pathway, stimulated by postsynaptic D2
receptors.25,26
3. Somatodendritic mechanisms, with dopamine acting on D2
receptors on dopamine cell bodies in the midbrain to decrease
dopamine neural activity and release.26,27
Apomorphine is considered a potent D1 and D2 receptor partial
agonist (with higher selectivity for D2), and is widely used for
Parkinson’s disease.28 Preclinical studies suggest it is a partial
dopamine agonist with 79% and 53% efﬁcacy relative to
dopamine at D2 receptor D2-short and D2-long splice variants,
respectively.29 Besides acting on postsynaptic dopamine
receptors, apomorphine has agonist effects on presynaptic
autoreceptors,30,31 has been used to measure the distribution of
dopamine autoreceptors32 and has been shown to have effects on
the basal ﬁring rate of dopamine neurons,33 and differential
effects on locomotor activity in rodents, depending on dosage.34
Apomorphine is therefore thought to act via one or more of the
autoregulatory mechanisms above, to regulate dopamine func-
tion. Supporting this, a study in rhesus monkeys showed that
apomorphine reduces DSC, and that this effect was greater in
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animals with greater baseline DSC.35 To date, in vivo studies in
humans have been limited to people with Parkinson’s disease
(PD), one [11C]-raclopride study ﬁnding evidence of reduced
dopamine release following amphetamine,36 and a study in early
and late PD, ﬁnding reduced DSC in early PD, but the numerically
opposite effect in late PD.37 The study of apomorphine in
Parkinson’s disease is problematic when looking at function
in non-disease populations, as animal literature suggests auto-
receptor sensitivity to be affected when damage to the
nigrostriatal system has occurred.38
Therefore, although these ﬁndings are consistent with an
autoregulatory effect of dopamine agonism in disease, the
regulation of DSC in healthy humans remains to be determined.
In view of this, we aimed to determine the relationship between
baseline dopamine synthesis capacity and the effect of dopamine
stimulation, using apomorphine, on dopamine synthesis capacity,
indexed using 18F-DOPA PET, in healthy humans. In study 1, we
determined the reliability of 18F-DOPA imaging and the relation-
ship between baseline DSC and change on re-scanning in
untreated healthy volunteers to provide reference data for
comparison. In study 2, we determined the effect of apomorphine
on DSC using doses designed to preferentially act on presynaptic
autoreceptors36,39 to test the hypothesis that apomorphine would
alter DSC, and that this would depend on baseline DSC.
MATERIALS AND METHODS
Ethical approval
Study 1 was approved by the South London and Maudsley/Institute of
Psychiatry NHS Trust. Study 2 was approved by the Hammersmith
Research Ethics Committee. The Administration of Radioactive Substances
Advisory Committee (ARSAC) granted permission to administer [18F]-DOPA
for both the studies.
Participants
All the participants gave written informed consent. The participants were
recruited through the local media. Inclusion criteria for all the subjects
were: male gender, age 18–35, no history of major medical illness, and
capacity to give written informed consent. The exclusion criteria for all the
participants were: presence of any signiﬁcant current medical disorder or
treatment including history of head injury resulting in loss of conscious-
ness and any neurological disorder; diagnosis of past or current psychiatric
disorders using the Structured Clinical Interview for DSM-IV40 including
alcohol or any other substance dependence or abuse. All the participants
provided urine samples on the day of the PET scans to screen for drug use
(Monitect HC12, Branan Medical, Irvine, CA, USA), and were excluded if
they were positive. No subject was taking psychotropic medication at the
time of study participation.
Study 1: test–retest study to determine the relationship between
baseline dopamine synthesis capacity and change in dopamine
synthesis capacity under resting (unstimulated) conditions
Eight healthy adults (mean age 23.6 ± 3.5 years, range 19–28 years, ﬁve
males, six right-handed) participated in this study as part of an ongoing
research project.41
PET data acquisition. Each subject received two 18F-DOPA PET scans,
administered approximately 2 years apart (mean± SD=113.6 ± 16 weeks).
PET imaging was performed on an ECAT/EXACT3D:Siemens/CTI (Knoxville,
TN, USA) PET tomograph (spatial resolution: 4.8 (0.2) mm; sensitivity:
69 cps Bq− 1 ml− 1). High-resolution images of the whole brain were
reconstructed from 95 planes with a section spacing of 2.425 mm. All
the participants were asked not to eat or drink (except water), and refrain
from alcohol for 12 h before the scan. The subjects received carbidopa
(150 mg) and entacapone (400 mg) orally about 1 h before imaging.42 The
administration of carbidopa and entacapone reduces the formation of
radiolabeled 18F-DOPA metabolites,43 increasing the signal-to-noise ratio.42
The 400 mg dose of entacapone used increases the amount of 18F-DOPA
signal in the plasma accounted for by unmetabolized 18F-DOPA from
approximately 21 to 55%.42 The subjects were positioned with the
orbitomeatal line parallel to the transaxial plane of the tomograph, and
head position was marked and monitored via laser crosshairs and a
camera. The head movement was minimized by a moulded head rest and
straps. A 5-min transmission image was obtained before radiotracer
injection using a 150 MBq caesium Cs 137 rotating point source to correct
for attenuation and scatter.
Emission data were acquired in list mode for 95 min, rebinned into 26
time frames (comprising a 30 s background frame, four 60 s frames, three
120 s frames, three 180 s frames and ﬁnally ﬁfteen 300 s frames), and
reconstructed using a three-dimensional re-projection algorithm. Further
details on the methods are reported in prior literature.44
Study 2: apomorphine challenge
Twelve healthy male volunteers (mean age 26.42, s.d. 5.14; 10 right-
handed) underwent 18F-DOPA PET scans on two separate occasions (mean
days between scans = 50.8 days (s.d. = 109.9)). They received a 2 ml
subcutaneous injection of either apomorphine or placebo (normal saline,
omitted in two subjects) approximately 30 min before the start of the scan.
The participants were blinded to whether they were given placebo or
apomorphine. The scanning time point was selected on the basis of the
pharmacokinetics to correspond to the peak period of action of
apomorphine. Apomorphine has been shown to have effects on aromatic
acid decarboxylase (AADC) in rat striatum within half an hour,45 and having
biological effects for up to 120 min in people with Parkinson’s disease.46
Apomorphine dose. Five subjects received apomorphine at a dose of
0.03 mg kg− 1 subcutaneously, based on a prior human study in
Parkinson’s disease,36 this dose also being in line with animal work.47
Three subjects experienced notable autonomic side effects (nausea in one
subject who had to leave the scanner and was excluded from analysis,
increased blood pressure and vasodilation in two).
Consequently, the dose was decreased to improve tolerability.22 A dose
of 0.0005 mg kg− 1 was chosen and given to eight volunteers on the basis
of behavioural and clinical studies,39,48 and we hypothesized that this
would not cause autonomic effects. In contrast to the higher dose, no side
effects were noted with the lower apomorphine dose.
PET data acquisition. Approximately 150 MBq of 18F-DOPA was adminis-
tered by bolus intravenous injection 30 s after the start of the PET imaging.
All the participants were asked not to eat or drink (except water), and
refrain from alcohol for 12 h before the scan. In study 2, the imaging data
were obtained on a Siemens CTI ECAT HR 962 PET scanner (Siemens,
Erlanger, Germany) in three-dimensional mode. One hour before the scan,
the participants received 400 mg Entacapone, a peripheral catechol-0-
methyl-transferase inhibitor, and 150 mg Carbidopa, a peripheral aromatic
acid decarboxylase inhibitor, to increase speciﬁc signal detection, as these
compounds decrease the formation of radiolabeled metabolites that may
cross the blood–brain barrier.43 The participants were positioned in the
scanner with the orbitomeatal line parallel to the transaxial plane of the
tomograph. The head position was marked and monitored and the
movement was minimized using a head strap.
The PET data were acquired in 32 frames of increasing duration over the
95 min scan (frame intervals: 8 × 15 s, 3 × 60 s, 5 × 120 s frames, 16 × 300 s).
PET analysis
For both the studies, image analysis was conducted as previously
described (please see Supplementary Information).49 The striatal inﬂux
constant (Kceri , written as Ki in some previous publications
41) was calculated
compared with uptake in the reference region using a graphical approach
adapted for a reference tissue input function.44
Statistical analysis
The percentage change in Ki
cer was calculated as: (baseline Kceri - K
cer
i after
apomorphine)/(baseline Kceri ) × 100. For the purpose of analysis, ‘baseline’
refers to when subjects were not given apomorphine challenge, that is,
when given either placebo or no compound.
Statistical analyses were performed using SPSS (Version 21.0, IBM,
Armonk, NY, USA),50 signiﬁcance was set at Po0.05 (two-tailed). Normality
of distribution for Ki
cer values and percentage change was assessed using
the Kolgoroff–Smirnov test. In study 1, we determined the test–retest
variability of repeat 18F-DOPA imaging as previously reported,44 and
determined relationships between baseline Kceri and difference between
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baseline and follow-up Kceri using Pearson’s correlation. In study 2, within-
subject differences baseline (placebo) and stimulated (apomorphine)
conditions were assessed using paired t-tests. A Pearson correlation
coefﬁcient was computed to assess relationships between baseline Kceri in
the whole striatum and change with apomorphine.
Testing for regression to the mean
To test whether our results may represent regression to the mean,51 we
conducted a one-way, repeated-measures analysis of variance to assess the
effect of group (test–retest or apomorphine challenge) × change (change
from baseline) interaction, with the hypothesis that partial agonist effects
of apomorphine (change in Ki
cer from baseline) would distinguish the
apomorphine challenge group from that of the test–retest sample. In the
analysis of variance, we used Levene’s test to test the null hypothesis that
the variance of the two groups was equal. We also utilized linear regression
to assess whether baseline Ki
cer and the apomorphine ×baseline Ki
cer
interaction could predict second scan Ki
cer. Finally, we tested the null
hypothesis that there would be no difference in means and variances of
both sets of measures (test–retest data set and those given apomorphine),
and the correlation between the sets of measures would be equal.52 For
this, we converted each correlation to a z-score, using Fisher’s r to z
transformation,53 then applying Steiger’s equations.54 A z-score based on
the difference between the two values and variance of the difference
between the two scores was obtained.55
RESULTS
Injected activity
Mean (s.d.) injected activity for Study 1 was 147.3 (6.6) MBq (scan
one) and 147.7 (2.7) MBq (scan two). There was no signiﬁcant
difference in activity injected between both the scans (t14 =− 0.16;
P= 0.88). Mean (s.d.) injected activity for Study 2 was 149.0 (9.4)
MBq (scan one) and 144.9 (5.5) MBq (scan two). There was no
signiﬁcant difference in the activity injected between both the
scans (t11 = 1.44; P= 0.18).
Study 1: reliability of 18F-DOPA PET imaging and the relationship
between baseline dopamine synthesis capacity and change over
time in untreated people
There was no signiﬁcant difference between scans (mean (s.d.)
Ki
cer values: scan 1 = 0.014 min− 1 (0.0015); scan 2 = 0.014 min−1
(0.0014)).
The interclass correlation for both the scans was 0.834, as
reported previously.44
The relationship between initial Kceri and change in K
cer
i over
time is shown in Figure 1. There was no signiﬁcant correlation
between initial Kceri and change in Ki
cer over time (r=− 0.57, n= 8,
P= 0.17; See Figure 1).
Study 2: the effects of apomorphine on dopamine synthesis
capacity
The effect of apomorphine on dopamine synthesis capacity is
shown in Figure 2.
There was no main effect of apomorphine on whole striatal
Ki
cer (t11 =− 0.71; P= 0.49); mean (s.d.) K
cer
i pre-apomorphine =
0.0120 (0.012) min− 1 and post-apomorphine = 0.0123
(0.0010) min− 1.
The mean (s.d.) difference (pre-apomorphine− post-apomor-
phine) for both doses was − 0.00025 (0.0013) min− 1, mean (s.d.)
percentage change =− 2.8% (1.1%).
The mean (s.d.) relative difference in dopamine synthesis
capacity between baseline and post-apomorphine was 5% (11%)
for 0.03 mg kg− 1 and 2% (10%) for 0.005 mg kg− 1.
There was no relationship between time between scans and
change in Ki
cer values (Spearman’s rho =− 0.161, P= 0.62, two-
tailed).
To exclude a potential effect of apomorphine on blood ﬂow in
the reference region (cerebellum),22 we examined the reference
region to see whether there was any change with administration
of apomorphine. No difference in (as measured by the standar-
dized uptake value at 95 min) was found (t10 = 0.78, P= 0.45).
Relationship between baseline Kceri and percentage change. There
was a signiﬁcant negative correlation between baseline value and
percentage change in K ceri with apomorphine, r=− 0.71,
n= 12, P= 0.01 (two-tailed; See Figure 3). Removal of the outlier,
identiﬁed in Figure 3, gave a correlation of − 0.9, n= 11, Po0.01.
This was larger, in absolute terms, in the subjects receiving the
lower dose of apomorphine (0.005 mg kg− 1, r=− 0.87, n= 8,
Po0.01), although the difference between the two dose ranges
was not statistically signiﬁcant.
There was no appreciable change in effect size or P-value when
the two subjects who did not receive placebo were excluded from
the analysis (r= 0.67, P= 0.034, two-tailed). There was no relation-
ship between time between scans and change in Ki
cer values
(Spearman’s rho =− 0.161, P= 0.62, two-tailed).
Figure 1. Ki
cer at baseline and follow-up, indicating no signiﬁcant
difference in dopamine synthesis capacity under rest conditions.
Figure 2. (a) Single-subject dopamine synthesis capacity at baseline
and following apomorphine. (b) Mean (s.d.) dopamine synthesis
capacity at baseline and following apomorphine.
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Testing for regression to the mean: analysis of variance, linear
regression and rate dependency bias analyses
Levene’s test indicated no statistically signiﬁcant difference in
variance between both the groups (P= 0.89).
On one-way repeated-measures analysis of variance, there was
a signiﬁcant group (test–retest or apomorphine challenge) ×
change (baseline and change from baseline) interaction, F
(1,18) = 11.5, P= 0.003.
We used linear regression to predict the second scan Ki
cer based
on baseline Ki
cer and baseline–apomorphine interaction. A
signiﬁcant regression equation was found (F = 16.6, P= 0.001),
with an adjusted R2 of 0.451, P= 0.001. These ﬁndings were
strengthened when the outlier (see Figure 3, above) was removed,
leading to an adjusted R2 of 0.647, with both baseline Ki
cer and
apomorphine–baseline interaction contributing to the model
(P= 0.02 and P= 0.01, respectively).
Using a two-tailed test of signiﬁcance, a signiﬁcant difference
was found between the correlation in the test–retest study and
apomorphine challenge study (with removal of the outlier, as
above, Po0.01).
DISCUSSION
Our main ﬁnding is that the regulation of DSC by a dopamine
partial agonist depends on baseline DSC. Speciﬁcally, people with
relatively high baseline dopamine synthesis show a reduction,
whereas those with relatively low baseline values show an
increase in DSC. This ﬁnding is consistent with apomorphine
stabilizing DSC as a partial agonist. Partial dopamine receptor
agonists increase dopamine receptor signalling if dopamine levels
are low and decrease dopamine receptor signalling when
dopamine levels are high as they compete with dopamine and
given their lower intrinsic activity the net output is lower than
dopamine per se. Moreover, we did not see a relationship between
baseline dopamine synthesis capacity and change over time in our
test–retest study, where there was no apomorphine administra-
tion, indicating that the effect seen with apomorphine is unlikely
to be explained by regression to the mean.
Comparison with other imaging studies
Our ﬁndings extend those of an L-11C-DOPA study of rhesus
monkeys, which also found a strong negative relationship
between baseline Ki value and apomorphine induced change in
Ki value (r=− 0.93), to show this in humans.
35 Our results are also
similar to ﬁndings from an L-11C-DOPA study carried out in
people with early- and late-stage Parkinson’s disease.37 Ekesbo
et al.37 found a signiﬁcant effect of stage of Parkinson’s disease on
the effect of apomorphine such that patients with early-stage
disease showed a reduction, whereas patients with late stage
showed an increase in DSC in absolute terms, though this was not
statistically signiﬁcant. The patients with early-stage disease who
showed a reduction with apomorphine had Ki values similar to
those in our subjects who showed a reduction with apomorphine,
whereas those with late-stage disease had low Ki values, lower in
absolute terms than in our subjects, who showed an increase. Our
ﬁndings thus extend these ﬁndings in non-human primates and
Parkinson’s disease to indicate that the normal regulation of DSC
also depends on baseline dopaminergic function.
Dopaminergic responses dependent on baseline dopamine
In addition to the studies discussed above, several other lines of
evidence show this dependency on baseline dopamine function.
In the Parkinson’s disease literature, animal and human studies
have shown using functional magnetic resonance imaging
increased the blood oxygen level-dependent activation in
dopamine-deﬁcient states, following apomorphine infusion.56–60
A human PET study, in early and advanced Parkinson’s disease,
showed that response to L-DOPA was dependent on baseline
status, with those with mild PD showing decreased striatal inﬂux
of L-DOPA, and those with advanced PD showing an increase in
striatal L-DOPA uptake.61 A recent rodent study, examined the
effects of aripiprazole (a partial dopamine agonist) on dopamine
synthesis in rodents, ﬁnding that its effects on presynaptic D2
autoreceptors was either as an agonist or antagonist, depending
on whether the experimental condition was of low or high
dopaminergic tone.62 This ﬁnding has also been seen in healthy
volunteers given the partial dopamine agonist aripiprazole or the
dopamine antagonists haloperidol or risperidone.63–65
Mechanism of action
Our ﬁndings are consistent with evidence that apomorphine acts
as a partial agonist at dopamine D2 receptors.
29 This indicates that
in healthy volunteers, with relatively high DSC and presumed
relatively low-tonic auto-inhibition by dopamine, apomorphine
will act as an agonist at autoreceptors, to decrease DSC.
Conversely, in healthy volunteers with relatively low DSC and
presumed relatively high tonic auto-inhibition by dopamine,
apomorphine will compete with dopamine to occupy the
autoreceptor. As apomorphine lacks the full agonist action, it will
decrease the net functional agonist effect when it displaces
dopamine, thereby causing increased DSC. This is in line with
competitive binding studies.29 The data from CHO-expressed
recombinant human D2S, D2L, D3 and D4 receptors measuring the
inﬂuence of apomorphine on [35S]GTPγS binding both alone and
in combination with dopamine points to it having partial agonist
effects, as noted above.29 Nevertheless, it is important to note that
partial agonism has not been shown in intact preparations, where
apomorphine is generally found to behave as a full agonist, so this
interpretation of our ﬁndings should be considered tentative at
this stage.
Limitations
Our study was not intended to examine dose effects. Conse-
quently, the sample size for the higher dose of apomorphine was
small, which means that our analysis of dose effects lacks power
and should be considered preliminary. It would be useful to use a
wider dose range in future work to deﬁnitively test the dose
effects. Our study design does not prove a causal relationship
Figure 3. Correlation between baseline Ki
cer and percentage change
in Ki
cer under apomorphine challenge (triangle= 0.03 mg kg− 1 dose,
circle= 0.005 mg kg− 1 dose), indicating that the effect of apomor-
phine on dopamine synthesis capacity depends on baseline
dopamine synthesis capacity.
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between baseline DSC and response to dopamine agonism. This
could be done in preclinical experiments using optogenetic or
other techniques to alter baseline DSC.
The test–retest comparison group had a longer duration of time
between scans than the apomorphine challenge group. Despite
this length of time, however, there was good test–retest reliability
between scans in this group, and no evidence of regression to the
mean. Nevertheless, it would be useful for future studies to test
this over the same duration as used in the challenge group. It
should also be noted that a few of the participants in the test–
retest study showed large absolute differences, of − 10% to 20%;
although at the group level, the variability was much less. This
likely reﬂects subject and scan acquisition-related variability, such
as small movements of the subject during one scan session.
However, this individual level variability would reduce our power
to detect the relationship between baseline dopamine synthesis
capacity and change under apomorphine. As such, it does not
account for our ﬁndings, and could reduce the strength of the
relationship.
Pharmacological considerations
Other considerations include possible effects of apomorphine on
blood ﬂow in the reference region (cerebellum), and the
possibility that apomorphine could have effects on the peripheral
elimination or metabolism of DOPA. However, these are unlikely
to explain our results for the following reasons. First, we did not
ﬁnd differences in DOPA uptake in the reference region pre- or
post-apomorphine. The consistency of 18F-DOPA activity in
cerebellum at baseline and after apomorphine that we found
would suggest that apomorphine is not having an effect on blood
ﬂow (please see Figure 1 and Supplementary Material). Never-
theless, further investigation using arterial blood sampling is
needed to deﬁnitively exclude any signiﬁcant alteration on blood
ﬂow by apomorphine at the dosage used in this study.
Although we were unable to test whether apomorphine would
affect metabolism of DOPA in our sample, previous animal
literature has failed to ﬁnd any effect.35 Assuming an effect of
apomorphine on blood ﬂow, as shown in preclinical studies,66 this
would have been uni-directional (either an increase or decrease
compared with baseline conditions) and in contrast to our
ﬁndings, which suggest bidirectional modulation of dopamine
synthesis. Two subjects did not receive placebo during baseline
scan, which may introduce an expectancy effect. However, taking
these two subjects out of the analysis did not signiﬁcantly change
magnitude of effect size or P-value, as shown above. We accept
that, in the subjects who reported side effects with apomorphine,
breaking of the blind could have occurred. This could have
potentially affected dopamine release in these individuals.67 It
should be noted, however, that in those people receiving
apomorphine at the lower dose (with no side effects) the results
were unchanged, and magnitude of correlation was larger.
It is conceivable that, as Ki is calculated from Ki=K1× k3(k2+k3),
which is a rectangular hyperbola, if Ki is higher, a change in k3 will
have different effects on Ki than when Ki is lower. We therefore ran
a simulation using standard values for K1, k2 and k3.68 We do not
know the real change in k3 but around control values the
relationship between Ki and k3 is not exactly linear. Assuming a
+30% change in k3, this would translate into a +33% change for
subjects with the largest Ki and in a +40% change for those with
the lowest Ki. Therefore, it is unlikely that our results reﬂect a
statistical artefact. It could also be hypothesized that the
conversion rate, k3, may be saturable, and therefore one would
not see a change in those with higher baseline Ki
cer. However our
results argue against this. In our study, similar changes were seen
in those with both high and low baseline Ki
cer, in keeping with
other pharmacological studies using the F-DOPA ligand, which
have shown a decrease in Ki
cer in those with relatively higher
baseline Ki
cer.63,69 Furthermore, in normal conditions, AADC is not
the rate-limiting step in dopamine synthesis and apomorphine at
the doses used in the study is not known to directly inﬂuence
AADC levels, but modiﬁes it functionally via dopamine receptors.70
In these conditions, tracer quantities of 18F-DOPA will not saturate
AADC. However, it should be noted that AADC may be saturable
when high doses of L-DOPA are given, for example, as a treatment
for Parkinson’s disease. Finally, it is worth examining the possible
acute and chronic effects of apomorphine. Animal work suggests
differential effects of apomorphine acutely (with a decrease in
striatal dopamine turnover with acute treatment, and an increase
with chronic treatment).71 In humans, chronic treatment with D2
partial agonists with high intrinsic activity, aimed at selectively
engaging the autoreceptors, has not been effective in treating
schizophrenia.72 The main reason attributed has been desensitiza-
tion of D2 autoreceptors. However, animal literature is mixed in
this regard.73,74
Therapeutic implications
Our ﬁnding that low-dose apomorphine has a stabilizing effect on
dopaminergic function has implications for the treatment of a
number of disorders in addition to Parkinson’s disease. In
schizophrenia, where DSC is predominantly elevated,13,14 our
ﬁndings indicate that a low level of dopamine agonism may act to
reduce elevated DSC. The low dose used suggests there will not
be signiﬁcant postsynaptic effects, reducing the risk of exacerbat-
ing psychosis or other side effects. Indeed, there is evidence of
efﬁcacy of apomorphine in schizophrenia, although initial positive
results75 were not replicated,72 possibly because doses used in
some studies were higher (up to 6 mg) than those we used, as well
as desensitization, as noted above. Dopamine agonism could also
have a role in substance dependence (particularly stimulant
dependence) to stabilize dopaminergic neurotransmission by
potentially providing tonic dopaminergic stimulation and redu-
cing surges in dopamine associated with drug-related cues. Our
ﬁndings support studies in these conditions to determine the
effect of dopaminergic stimulation on dopamine function.
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